OBJECTIVES: Glaucoma is associated with elevated pressure in the eye (intraocular pressure) that may cause injury to the eye if not treated, and as a result, lead to blindness. The aim of this study was to identify the types of drug treatments that were used between 2013 and 2014 in Brazil. METHODS: Patients were identified through the health insurance database of Brazil, from January 2013 to December 2014. The patients were selected with ICD-H40 and its subcategories and bought antiglaucoma drugs in the analyzed period. From the date of the purchase, it's possible to obtain a methodology capable of identifying if a patient has used more than a drug for the treatment. It was then possible to find the main associations of glaucoma ophthalmic solutions. RESULTS: From a total of 169,741 patients who bought some kind of antiglaucoma medication, 53,228 used more than one type of eye drop. The molecules analyzed were: Timolol, Dorzolamide, Brimonidine, Brinzolamide, Travoprost, Bimatoprost and Latanoprost. Since Timolol was the most representative drug of this period on purchases and was present in 36.7 % of the total purchases, with or without association with another molecule, it has been selected the three most representative associations in the sample under study. It has been found that Timolol associated with Dorzolamide corresponded to 22.8 % of the procurement, followed by associations between Timolol and Brimonidine (21.2 %) and Brinzolamide and Timolol (11.2%). CONCLUSIONS: Approximately 40% of the patients in supplementary health sample from Brazil make use of more than one drug for Glaucoma treatment, this fact confirms the protocol realized by Brazil's Health Ministry, where it is described that the therapeutic class, block beta-receptor, is the main class for treat Glaucoma and it is usually combined with another antiglaucoma class to reduce the intraocular pressure.